SOPHiA GENETICS today announced the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine. The round was led by Generation Investment Management, a pioneer of sustainable investing. Balderton joined the round, along with Idinvest Partners and Alychlo.
SOPHiA GENETICS was founded in Switzerland and is now co-based in Lausanne and Boston. The company combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing. Today, its universal platform, SOPHiA AI, is utilized by more than 850 hospitals across 77 countries and has already supported the diagnosis of over 300,000 patients. The platform enables healthcare professionals to make sense of complex genomic and radiomic data through advanced analysis in order to better diagnose and treat patients, both for oncology and hereditary disorders.
Sophia stands out as one of the most exciting companies in genomic software in the world today.
